BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32444465)

  • 1. Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia.
    Zhou Y; Han C; Wang E; Lorch AH; Serafin V; Cho BK; Gutierrez Diaz BT; Calvo J; Fang C; Khodadadi-Jamayran A; Tabaglio T; Marier C; Kuchmiy A; Sun L; Yacu G; Filip SK; Jin Q; Takahashi YH; Amici DR; Rendleman EJ; Rawat R; Bresolin S; Paganin M; Zhang C; Li H; Kandela I; Politanska Y; Abdala-Valencia H; Mendillo ML; Zhu P; Palhais B; Van Vlierberghe P; Taghon T; Aifantis I; Goo YA; Guccione E; Heguy A; Tsirigos A; Wee KB; Mishra RK; Pflumio F; Accordi B; Basso G; Ntziachristos P
    Cancer Discov; 2020 Sep; 10(9):1388-1409. PubMed ID: 32444465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia.
    Han C; Khodadadi-Jamayran A; Lorch AH; Jin Q; Serafin V; Zhu P; Politanska Y; Sun L; Gutierrez-Diaz BT; Pryzhkova MV; Abdala-Valencia H; Bartom ET; Buldini B; Basso G; Velu SE; Sarma K; Mattamana BB; Cho BK; Obeng RC; Goo YA; Jordan PW; Tsirigos A; Zhou Y; Ntziachristos P
    Sci Adv; 2022 Jan; 8(3):eabj8357. PubMed ID: 35061527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM.
    Zhang F; Wang H; Yu J; Yao X; Yang S; Li W; Xu L; Zhao L
    Mol Cancer; 2021 Jan; 20(1):6. PubMed ID: 33397371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia.
    Ajiro M; Awaya T; Kim YJ; Iida K; Denawa M; Tanaka N; Kurosawa R; Matsushima S; Shibata S; Sakamoto T; Studer L; Krainer AR; Hagiwara M
    Nat Commun; 2021 Jul; 12(1):4507. PubMed ID: 34301951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SF2 and SRp55 regulation of CD45 exon 4 skipping during T cell activation.
    Lemaire R; Winne A; Sarkissian M; Lafyatis R
    Eur J Immunol; 1999 Mar; 29(3):823-37. PubMed ID: 10092085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RNA-binding profile of the splicing factor SRSF6 in immortalized human pancreatic β-cells.
    Alvelos MI; Brüggemann M; Sutandy FR; Juan-Mateu J; Colli ML; Busch A; Lopes M; Castela Â; Aartsma-Rus A; König J; Zarnack K; Eizirik DL
    Life Sci Alliance; 2021 Mar; 4(3):. PubMed ID: 33376132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxic ischemia and proteasome dysfunction alter tau isoform ratio by inhibiting exon 10 splicing.
    Suh J; Im DS; Moon GJ; Ryu KS; de Silva R; Choi IS; Lees AJ; Guénette SY; Tanzi RE; Gwag BJ
    J Neurochem; 2010 Jul; 114(1):160-70. PubMed ID: 20374429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples.
    Lu BY; Thanawala SU; Zochowski KC; Burke MJ; Carroll WL; Bhatla T
    Leuk Lymphoma; 2016 Aug; 57(8):1938-41. PubMed ID: 26726842
    [No Abstract]   [Full Text] [Related]  

  • 9. USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia.
    Jin Q; Martinez CA; Arcipowski KM; Zhu Y; Gutierrez-Diaz BT; Wang KK; Johnson MR; Volk AG; Wang F; Wu J; Grove C; Wang H; Sokirniy I; Thomas PM; Goo YA; Abshiru NA; Hijiya N; Peirs S; Vandamme N; Berx G; Goosens S; Marshall SA; Rendleman EJ; Takahashi YH; Wang L; Rawat R; Bartom ET; Collings CK; Van Vlierberghe P; Strikoudis A; Kelly S; Ueberheide B; Mantis C; Kandela I; Bourquin JP; Bornhauser B; Serafin V; Bresolin S; Paganin M; Accordi B; Basso G; Kelleher NL; Weinstock J; Kumar S; Crispino JD; Shilatifard A; Ntziachristos P
    Clin Cancer Res; 2019 Jan; 25(1):222-239. PubMed ID: 30224337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poison cassette exon splicing of SRSF6 regulates nuclear speckle dispersal and the response to hypoxia.
    de Oliveira Freitas Machado C; Schafranek M; Brüggemann M; Hernández Cañás MC; Keller M; Di Liddo A; Brezski A; Blümel N; Arnold B; Bremm A; Wittig I; Jaé N; McNicoll F; Dimmeler S; Zarnack K; Müller-McNicoll M
    Nucleic Acids Res; 2023 Jan; 51(2):870-890. PubMed ID: 36620874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose proteasome inhibition affects alternative splicing.
    Bieler S; Hammer E; Gesell-Salazar M; Völker U; Stangl K; Meiners S
    J Proteome Res; 2012 Aug; 11(8):3947-54. PubMed ID: 22702956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitination regulates expression of the serine/arginine-rich splicing factor 1 (SRSF1) in normal and systemic lupus erythematosus (SLE) T cells.
    Moulton VR; Gillooly AR; Tsokos GC
    J Biol Chem; 2014 Feb; 289(7):4126-34. PubMed ID: 24368769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer.
    Chen S; Yang C; Wang ZW; Hu JF; Pan JJ; Liao CY; Zhang JQ; Chen JZ; Huang Y; Huang L; Zhan Q; Tian YF; Shen BY; Wang YD
    J Hematol Oncol; 2021 Apr; 14(1):60. PubMed ID: 33849617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Par-4/THAP1 complex and Notch3 competitively regulated pre-mRNA splicing of CCAR1 and affected inversely the survival of T-cell acute lymphoblastic leukemia cells.
    Lu C; Li JY; Ge Z; Zhang L; Zhou GP
    Oncogene; 2013 Dec; 32(50):5602-13. PubMed ID: 23975424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.
    Li Z; Younger K; Gartenhaus R; Joseph AM; Hu F; Baer MR; Brown P; Davila E
    J Clin Invest; 2015 Mar; 125(3):1081-97. PubMed ID: 25642772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between Hedgehog pathway and the glucocorticoid receptor pathway as a basis for combination therapy in T-cell acute lymphoblastic leukemia.
    Bongiovanni D; Tosello V; Saccomani V; Dalla Santa S; Amadori A; Zanovello P; Piovan E
    Oncogene; 2020 Oct; 39(42):6544-6555. PubMed ID: 32917954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
    Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
    Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing.
    Li Y; Xu J; Lu Y; Bian H; Yang L; Wu H; Zhang X; Zhang B; Xiong M; Chang Y; Tang J; Yang F; Zhao L; Li J; Gao X; Xia M; Tan M; Li J
    Cell Metab; 2021 Oct; 33(10):2004-2020.e9. PubMed ID: 34614409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia.
    Wu X; Wang L; Qiu Y; Zhang B; Hu Z; Jin R
    Int J Nanomedicine; 2017; 12():8025-8034. PubMed ID: 29184402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant splicing in B-cell acute lymphoblastic leukemia.
    Black KL; Naqvi AS; Asnani M; Hayer KE; Yang SY; Gillespie E; Bagashev A; Pillai V; Tasian SK; Gazzara MR; Carroll M; Taylor D; Lynch KW; Barash Y; Thomas-Tikhonenko A
    Nucleic Acids Res; 2018 Nov; 46(21):11357-11369. PubMed ID: 30357359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.